Characteristic
|
PsO studies
|
PsA studies
|
AS studies
|
---|
Any secukinumab
N = 5181
|
Any secukinumab
N = 1380
|
Any secukinumab
N = 794
|
---|
Age (years), mean (SD)
|
45.7 (13.3)
|
48.8 (12.0)
|
42.4 (12.3)
|
Female, n (%)
|
1743 (33.6)
|
742 (53.8)
|
265 (33.4)
|
Caucasian, n (%)
|
4236 (81.8)
|
1212 (87.8)
|
612 (77.1)
|
BMI, mean (SD)
|
29.1 (6.6)
|
29.8 (6.3)
|
27.2 (5.5)
|
Relevant medical history or current medical condition, n (%)
|
Hypertension
|
1089 (21.0)
|
551 (39.9)
|
176 (22.2)
|
Hyperlipidemia
|
667 (12.9)
|
318 (23.0)
|
65 (8.2)
|
Diabetes mellitus
|
341 (6.6)
|
171 (12.4)
|
22 (2.8)
|
IBD
|
0 (0)
|
4 (0.3)
|
17 (2.1)
|
Crohn’s disease
|
5 (0.1)
|
2 (0.1)
|
5 (0.6)
|
Ulcerative colitis
|
10 (0.2)
|
2 (0.1)
|
3 (0.4)
|
Uveitis
|
0 (0)
|
8 (0.6)
|
135 (17.0)
|
Current smoker
|
1585 (30.6)
|
262 (19.0)
|
234 (29.5)
|
Anti-TNF inadequate responder
|
784 (15.1)
|
435 (31.5)
|
227 (28.6)
|
- AS ankylosing spondylitis, BMI body mass index, IBD inflammatory bowel disease, N number of patients in the analysis, n number of patients with a response, PsA psoriatic arthritis, PsO psoriasis, SD standard deviation, TNF tumor necrosis factor